Baron Silver Stevens Financial Advisors LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Baron Silver Stevens Financial Advisors LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 10.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 834 shares of the medical research company’s stock after buying an additional 79 shares during the quarter. Baron Silver Stevens Financial Advisors LLC’s holdings in Amgen were worth $217,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Endeavor Private Wealth Inc. bought a new position in shares of Amgen during the fourth quarter valued at approximately $150,000. Raleigh Capital Management Inc. boosted its position in shares of Amgen by 29.1% in the 4th quarter. Raleigh Capital Management Inc. now owns 4,779 shares of the medical research company’s stock worth $1,246,000 after purchasing an additional 1,077 shares in the last quarter. Adirondack Trust Co. grew its stake in shares of Amgen by 3.0% in the 4th quarter. Adirondack Trust Co. now owns 2,978 shares of the medical research company’s stock worth $776,000 after buying an additional 88 shares during the last quarter. Traynor Capital Management Inc. increased its position in Amgen by 32.9% during the 4th quarter. Traynor Capital Management Inc. now owns 861 shares of the medical research company’s stock valued at $224,000 after buying an additional 213 shares in the last quarter. Finally, GoalVest Advisory LLC raised its stake in Amgen by 99.7% during the fourth quarter. GoalVest Advisory LLC now owns 1,202 shares of the medical research company’s stock valued at $313,000 after buying an additional 600 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ AMGN opened at $273.44 on Thursday. The business’s fifty day moving average is $271.91 and its 200 day moving average is $306.43. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a market capitalization of $146.98 billion, a PE ratio of 35.01, a price-to-earnings-growth ratio of 2.79 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $4.96 EPS. Sell-side analysts predict that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.48%. Amgen’s dividend payout ratio is 115.24%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on AMGN shares. Deutsche Bank Aktiengesellschaft cut their target price on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research note on Tuesday, October 22nd. Leerink Partners dropped their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Royal Bank of Canada reduced their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Finally, Wells Fargo & Company lowered their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.